Lilly Options Hit 2.8-Sigma Peak the Day Before Q3

Eli Lilly and Company closed Tuesday at $1,281.91, up a fraction on the day, one session before its Q3 results land, with options traders now more defensively positioned than at any point in the past year.

The options signal is the sharpest data point in the snapshot. The put/call ratio reached 1.26 on Tuesday, 2.76 standard deviations above its 20-day average of 1.18. That is the most extreme defensive reading of the past 52 weeks, whose low was 0.76 and whose prior high was 1.37. The move has accelerated over four consecutive sessions, from 1.19 on October 21 to 1.23 on Monday to 1.26 now. Put buyers have been outpacing call buyers into each day's close as the print approaches.

Short interest tells a much quieter story. Shares held short edged up 3% on Tuesday to 7.5 million, roughly 0.84% of the free float. That is a modest 3% gain on the week and down nearly 10% over the past month. Borrowing costs have also retreated, falling 13% on the week to 0.22%, their lowest level in six weeks. The lending pool remains effectively unconstrained: availability is nowhere near a ceiling. There is no crowded-short setup, no squeeze pressure, and the short score of 30.5 has barely moved in two weeks. Shorts are not driving this story.

The Street remains broadly constructive into the print. Several analysts lifted targets in October, with Morgan Stanley raising to $1,430 and Cantor Fitzgerald moving to $1,440, both maintaining positive ratings. RBC and JP Morgan sit at $1,500, the top of the range. The mean target is $1,334, roughly 4% above Tuesday's close. The one dissenting voice in recent months is HSBC, which carries a Reduce rating with a target well below current levels; that data point is now six weeks old but the rating direction has not changed. Factor scores lean positive: analyst recommendation difference ranks in the 93rd percentile, EPS surprise in the 75th, and earnings yield in the 74th. The valuation multiple that has moved most is price-to-book, up roughly 1.2 points over 30 days to 16.1x, a reflection of the month's 8% price gain. The bull case rests on Zepbound and Mounjaro volume momentum and a projected guidance increase of around $2 billion. The bear case centres on Verzenio and Trulicity missing expectations, an expected $4.2 billion IPR&D charge, and MFN pricing that persists through year-end.

Retail attention has also picked up. Wikipedia views and ORTEX page traffic for Lilly are running at a combined z-score of 2.2 against the company's own 90-day history, the highest attention reading in that window. The dataset publisher is the Wikimedia Foundation. This measures interest, not revenue, but the timing one day before the print is notable.

The stock has added roughly 8% since October 9. Both prior reported quarters produced positive reactions: August's Q2 release moved the stock 6.8% on the day and 9.4% over the following five sessions. May's Q1 release was more restrained at 2.7% on the day, flat over five days. The Q3 print on October 29 is therefore the next data point that determines whether the pre-earnings run was front-running a beat or pricing in expectations the results cannot clear.